

	General Population		IBD*		IBD-SI		Wilcoxon test p-value	
	Mean [SD] or Count [Proportion, %]	NA [n]	Mean [SD] or Count [Proportion, %]	NA [n]	Mean [SD] or Count [Proportion, %]	NA [n]	General Population vs IBD-SI	IBD* vs IBD-SI
Number of samples [n]								
Sequencing read depth [SD]	32919455 [12276237]	0	25031114 [10203888]	3	22828376 [10140543]	0	1.33E-09	0.138995323
Sex [female/male]	689/489 [58/42%]	0	285/193 [60/40%]	0	42/15 [74/26%]	0	0.022680447	0.039735647
Age at time of faecal sampling [SD]	45 [13.6]	0	42.9 [12.8]	0	45.2 [10.9]	0	0.968143509	0.131811149
Body mass index [SD]	25.3 [4.2]	0	25.4 [5.0]	6	26.4 [6.85]	1	0.650352121	0.630972528
Faecal calprotectin level over 200 mg/kg [n/y] [%]	1124/48 [96/4%]	6	238/185 [56/44%]	55	32/10 [76/24%]	15	4.03E-09	0.012657476
C-reactive protein levels in mg/L divided by 5 [SD]	NA	1178	1.7 [1.9]	2	1.75 [2.13]	0	NA	0.695116431
Current IBD diagnosis [CD/IBDU/UC] [%]	NA	0	274/29/175 [57/6/37%]	0	23/1/33 [40/2/58%]	0	NA	0.005233266
Disease duration of IBD in years [SD]	NA	1178	11.8 [8.8]	8	16.6 [10.4]	0	NA	0.000410007
IBD disease activity – based on SCCAI and HBI scores [active/not active] [%]	NA	1178	114/358 [24/76%]	6	5/52 [9/91%]	0	NA	0.008679626
Disease location of IBD [both/colon/ileum] [%]	NA	1178	111/221/97 [26/51/23%]	49	14/36/2 [27/69/4%]	5	NA	0.05559574
Ever had a stoma or ileostomy pouch [n/y] [%]	NA	1178	446/32 [93/7%]	0	0/57 [0/100%]	0	NA	2.27E-71
Previous intestinal resections in IBD [n/y] [%]	NA	1178	309/169 [65/35%]	0	0/57 [0/100%]	0	NA	1.05E-20
Number of intestinal resections IBD [SD]	NA	1178	0.82 [1.6]	0	2.53 [2.28]	2	NA	1.15E-18
Ileocecal valve in situ [n/y]	NA	1178	123/351 [26/74%]	4	52/3 [95/5%]	2	NA	1.53E-24
Total stools formed per 24hrs [SD]	1.4 [0.7]	47	2.65 [2.34]	0	2.56 [3.77]	0	0.001870973	0.000157164
Immunosuppressants use [n/y] [%]	NA	1178	256/205 [56/44%]	17	37/15 [71/29%]	5	NA	0.031106634
AntiTNFs use [n/y] [%]	NA	1178	357/121 [75/25%]	0	50/7 [88/12%]	0	NA	0.029402356
Thiopurines use [n/y] [%]	NA	1178	319/159 [67/33%]	0	51/6 [89/11%]	0	NA	0.000447962
Antidiarrhoea use [n/y] [%]	NA	1178	412/49 [89/11%]	17	49/3 [94/6%]	5	NA	0.271482266
Bile acids use [n/y] [%]	NA	1178	437/24 [95/5%]	17	49/3 [94/6%]	5	NA	0.863254283
ACE inhibitor use [n/y] [%]	1091/44 [96/4%]	43	455/23 [95/5%]	0	56/1 [98/2%]	0	0.41227688	0.292318977
Angiotensin II receptor antagonist use [n/y] [%]	1101/34 [97/3%]	43	467/11 [98/2%]	0	55/2 [96/4%]	0	0.825236536	0.576077019
Antihistamine use [n/y] [%]	1066/69 [94/6%]	43	461/17 [96/4%]	0	53/4 [93/7%]	0	0.773224751	0.203838823
Antibiotics use [n/y] [%]	1165/13 [99/1%]	0	467/11 [98/2%]	0	54/3 [95/5%]	0	0.006704643	0.185885969
Benzodiazepine derivatives use [n/y] [%]	1107/28 [98/2%]	43	459/19 [96/4%]	0	55/2 [96/4%]	0	0.62427707	0.864119807
Beta-blockers use [n/y] [%]	1115/63 [95/5%]	0	443/35 [93/7%]	0	49/8 [86/14%]	0	0.00594789	0.0783367
Beta-sympathomimetic inhaler use [n/y] [%]	1070/65 [94/6%]	43	463/15 [97/3%]	0	54/3 [95/5%]	0	0.882948381	0.400759801
Bisphosphonates use [n/y] [%]	1125/10 [99/1%]	43	464/14 [97/3%]	0	53/4 [93/7%]	0	0.0000274	0.105948295
Calcium channel blocker use [n/y] [%]	1114/21 [98/2%]	43	470/8 [98/2%]	0	55/2 [96/4%]	0	0.374611026	0.334080832
Calcium use [n/y] [%]	1164/14 [99/1%]	0	395/83 [83/17%]	0	47/10 [82/18%]	0	2.49E-18	0.973008941
Iron preparations use [n/y] [%]	1171/7 [99/1%]	0	460/18 [96/4%]	0	51/6 [89/11%]	0	7.34E-13	0.019880859
Folic acid use [n/y] [%]	1171/7 [99/1%]	0	444/34 [93/7%]	0	53/4 [93/7%]	0	0.000000468	0.978869397
Laxatives use [n/y] [%]	1114/21 [99/1%]	43	447/31 [94/6%]	0	53/4 [93/7%]	0	0.007918352	0.878043045
Mesalazines use [n/y] [%]	1129/6 [99/1%]	43	310/168 [65/35%]	0	52/5 [91/9%]	0	2.17E-10	0.0000582
Metformin use [n/y] [%]	1162/16 [99/1%]	0	472/6 [99/1%]	0	55/2 [96/4%]	0	0.185963733	0.185554342
NSAID use [n/y] [%]	1093/42 [96/4%]	43	448/30 [94/6%]	0	55/2 [96/4%]	0	0.940326774	0.40539988
Opiates use [n/y] [%]	1122/13 [99/1%]	43	473/5 [99/1%]	0	55/2 [96/4%]	0	0.118446382	0.122305559
Oral contraceptive use [n/y] [%]	1019/116 [90/10%]	43	420/58 [88/12%]	0	56/1 [98/2%]	0	0.036135809	0.018152845
Oral steroid use [n/y] [%]	1173/5 [99/1%]	0	384/94 [80/20%]	0	47/10 [82/18%]	0	1.05E-30	0.702312302
Antidepressants use [n/y] [%]	1125/10 [99/1%]	43	457/21 [96/4%]	0	53/4 [93/7%]	0	0.0000274	0.375357542
Paracetamol use [n/y] [%]	1166/12 [99/1%]	0	434/44 [91/9%]	0	55/2 [96/4%]	0	0.082379844	0.14742216
Platelet aggregation inhibitor use [n/y] [%]	1101/34 [97/3%]	43	451/27 [94/6%]	0	53/4 [93/7%]	0	0.091814089	0.676119002
Proton pump inhibitor [n/y] [%]	1079/99 [92/8%]	0	366/112 [77/23%]	0	37/20 [65/35%]	0	2.64E-11	0.053880957
SSRI-antidepressant use [n/y] [%]	1106/29 [97/3%]	43	469/9 [98/2%]	0	57/0 [100/0%]	0	0.221991439	0.29657215
Statins use [n/y] [%]	1079/56 [95/5%]	43	447/31 [94/6%]	0	54/3 [95/5%]	0	0.910998854	0.720945956
Steroid inhaler use [n/y] [%]	1078/57 [95/5%]	43	459/19 [96/4%]	0	55/2 [96/4%]	0	0.607418172	0.864119807
Steroid nose spray use [n/y] [%]	1079/56 [95/5%]	43	473/5 [99/1%]	0	55/2 [96/4%]	0	0.625700166	0.122305559
Thiazide diuretic use [n/y] [%]	1092/43 [96/4%]	43	466/12 [97/3%]	0	56/1 [98/2%]	0	0.426920135	0.726271253
Levothyroxine use [n/y] [%]	1109/26 [98/2%]	43	468/10 [98/2%]	0	55/2 [96/4%]	0	0.553695825	0.495158799
Tryptic antidepressant use [n/y] [%]	1124/11 [99/1%]	43	467/11 [98/2%]	0	57/0 [100/0%]	0	0.455430863	0.247608241
Triptans use [n/y] [%]	1115/20 [98/2%]	43	473/5 [99/1%]	0	57/0 [100/0%]	0	0.312355796	0.438298036
Vitamin B12 use [n/y] [%]	1168/10 [99/1%]	0	387/91 [81/19%]	0	44/13 [77/23%]	0	5.01E-33	0.497073848
Vitamin D [n/y] [%]	1164/14 [99/1%]	0	403/75 [84/16%]	0	44/13 [77/23%]	0	1.2E-27	0.171099283